Related Experiment Video
Updated: Jul 2, 2026

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models
Published on: August 9, 2012
Development of UROGRAFT: A Bladder Acellular Matrix-Based Composite for Advanced Cystoplasty, Highlighting the Role
Marta Pokrywczynska1, Zuzanna Fekner1, Daria Balcerczyk1
1Chair of Urology and Andrology, Department of Regenerative Medicine, Nicolaus Copernicus University in Torun, Medical College in Bydgoszcz, Sklodowskiej-Curie M. Street, Bydgoszcz 85-094, Poland.
Abstract:
Urinary bladder augmentation with gastrointestinal segments, despite many complications, remains a gold standard treatment of low-capacity, poorly compliant, or refractory overactive urinary bladder. In this study, we developed the UROGRAFT, a new bladder acellular matrix-collagen-cellulose (BAM-CC) composite for urinary bladder augmentation. The study presents the step-by-step development process of UROGRAFT, including the selection of an optimal decellularization protocol and cross-linking method to ensure optimal biomaterial properties. Histological and biochemical analyses demonstrated that the combined protocol of Triton X-100 and sodium dodecyl sulfate (SDS) was the most effective, completely removing cellular components while preserving the extracellular matrix (ECM). DNA quantification confirmed a significant reduction in residual genetic material, ensuring a low immunogenic profile. Scanning electron microscopy (SEM) confirmed high porosity and well-preserved collagen fibers. To reduce porosity and permeability, BAM was cross-linked with collagen type I and dialdehyde carboxymethyl cellulose, optimizing scaffold performance. Biocompatibility tests confirmed the absence of toxicity, tissue reactions, acute systemic toxicity, and mutagenic effects. Based on computational modeling, verified by implantation trials, a unique three-armed graft shape resembling lily petals was developed. A preclinical study in porcine models demonstrated that UROGRAFT is highly biocompatible, well-tolerated, and safe for urinary bladder augmentation. Composite BAM-CC scaffolds provide an appropriate environment for adipose derived mesenchymal stromal cells (AD-MSCs) growth; therefore, the UROGRAFT can be used in the future as an acellular graft (biomedical device) or a cell-seeded tissue-engineered product (combined ATMP-biomedical device). UROGRAFT developed in this study is a promising new product with the potential to be used in augmentation cystoplasty, offering a safe and effective alternative to gastrointestinal segments.

